News Release

deCODE genetics: Rare sequence variants, that associate with a high risk of Parkinson‘s Disease

Peer-Reviewed Publication

deCODE genetics

Authors on the paper deCODE genetics: Rare sequence variants, that associate with a high risk of Parkinson‘s Disease

image: 

Astros Th. Skuladottir, first author on the paper, Rare sequence variants, that associate with a high risk of Parkinson‘s Disease, Kari Stefansson, CEO of deCODE genetics, is senior author on the paper. 

view more 

Credit: deCODE genetics

Scientists at deCODE genetics, a subsidiary of AMGEN, have discovered rare sequence variants, predicted to cause a loss of function of ITSN1, that are associated with a high risk of Parkinson‘s Disease. The findings also support less studied pathways involved in the pathogenesis of the disease.

The study, published today in npj Parkinson‘s Disease, used whole-genome sequence data from Iceland (deCODE genetics), the UK (UK Biobank), and the US (Accelerating Medicines Partnership Parkinson‘s disease).

The role of ITSN1, Intersectin-1, is to activate CDC42, a small Rho GTPase involved in the growth and maintenance of dopaminergic neurons and the regulation of vesicle exocytosis of α-synuclein, whose accumulation is a pathological hallmark of Parkinson‘s Disease. The researchers propose that loss of ITSN1 function may contribute to Parkinson‘s Disease pathogenesis through inactive CDC42 and its downstream pathways, degeneration of dopaminergic neurons and dysregulated vesicle exocytosis of α-synuclein, and/or through disrupted synaptic vesicle transport via clathrin-mediated endo- and exocytosis. This suggests that targeting CDC42 or its upstream regulator, ITSN1, might offer a therapeutic approach for Parkinson's Disease.


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.